Sato Yu, Kumamoto Kensuke, Saito Katsuharu, Okayama Hirokazu, Hayase Suguru, Kofunato Yasuhide, Miyamoto Koutaro, Nakamura Izumi, Ohki Shinji, Koyama Yoshihisa, Takenoshita Seiichi
Department of Organ Regulatory Surgery, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.
Exp Ther Med. 2011 Mar;2(2):239-243. doi: 10.3892/etm.2011.210. Epub 2011 Jan 20.
Annexin A1 (ANXA1) is a calcium-dependent phospholipid-linked protein, involved in anti-inflammatory effects, regulation of cellular differentiation, proliferation and apoptosis. In the present study, we investigated the expression of ANXA1 in gastric and colon cancer, and analyzed the relationship between ANXA1 expression and clinicopathological factors. ANXA1 mRNA expression in gastric and colon cancer tissues was not significantly changed compared to that in normal tissues. When ANXA1 protein expression was evaluated by immunohistochemical staining, ANXA1 expression was observed in 76 of 135 cases of gastric cancer (56.3%), and correlations were found between ANXA1 expression and depth of wall invasion (P<0.001), lymphatic invasion (P=0.023), venous invasion (P=0.002), lymph node metastasis (P=0.001) and UICC stage (P<0.001). Disease-specific survival rate was significantly lower in cases with ANXA1 expression compared to that in cases without (P=0.0053). In colon cancer, ANXA1 expression was detected in 61 of 210 cases (29.0%) and correlations were found with gender (P=0.038), lymphatic invasion (P=0.011), venous invasion (P=0.023), lymph node metastasis (P=0.042) and UICC stage (P=0.041). The disease-specific survival rate tended to be lower in cases with ANXA1 expression, although the differences were not statistically significant (P=0.6984). Our results indicate that up-regulated ANXA1 expression is involved in cancer invasion and lymph node metastasis. Furthermore, high levels of ANXA1 expression were implicated in poor prognosis of patients. ANXA1 may be applicable as a prognostic biomarker in gastric and colon cancer, and a potential target for treatment.
膜联蛋白A1（ANXA1）是一种钙依赖性磷脂结合蛋白，参与抗炎作用、细胞分化、增殖和凋亡的调节。在本研究中，我们调查了ANXA1在胃癌和结肠癌中的表达，并分析了ANXA1表达与临床病理因素之间的关系。与正常组织相比，胃癌和结肠癌组织中ANXA1 mRNA表达无明显变化。通过免疫组织化学染色评估ANXA1蛋白表达时，135例胃癌中有76例（56.3%）观察到ANXA1表达，且发现ANXA1表达与壁浸润深度（P<0.001）、淋巴浸润（P=0.023）、静脉浸润（P=0.002）、淋巴结转移（P=0.001）和UICC分期（P<0.001）之间存在相关性。与无ANXA1表达的病例相比，有ANXA1表达的病例疾病特异性生存率显著降低（P=0.0053）。在结肠癌中，210例中有61例（29.0%）检测到ANXA1表达，并发现其与性别（P=0.038）、淋巴浸润（P=0.011）、静脉浸润（P=0.023）、淋巴结转移（P=0.042）和UICC分期（P=0.041）相关。尽管差异无统计学意义（P=0.6984），但有ANXA1表达的病例疾病特异性生存率有降低趋势。我们的结果表明，ANXA1表达上调与癌症侵袭和淋巴结转移有关。此外，高水平的ANXA1表达与患者预后不良有关。ANXA1可能作为胃癌和结肠癌的预后生物标志物以及潜在的治疗靶点。
